CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis

Company Overview

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

Key Stats

• Today's Range: $3.97 to $4.41
• 50-Day Range: $3.71 to $4.93
• 52-Week Range: $3.61 to $6.99
• Volume: 9,184 shs
• Average Volume: 10,173 shs
• Market Capitalization: $48.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Strong Buy

CollPlant Biotechnologies Stock Analysis - MarketRank™

CollPlant Biotechnologies scored higher than 37% of companies evaluated by MarketBeat, and ranked 686th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

CollPlant Biotechnologies has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

CollPlant Biotechnologies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CollPlant Biotechnologies are expected to grow in the coming year, from ($1.44) to ($0.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CollPlant Biotechnologies is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CollPlant Biotechnologies is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CollPlant Biotechnologies has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.20% of the float of CollPlant Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

CollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CollPlant Biotechnologies has recently increased by 6.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CollPlant Biotechnologies does not currently pay a dividend.

Dividend Growth

CollPlant Biotechnologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.20% of the float of CollPlant Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

CollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CollPlant Biotechnologies has recently increased by 6.21%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for CLGN on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added CollPlant Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.60% of the stock of CollPlant Biotechnologies is held by insiders.

Percentage Held by Institutions

Only 21.69% of the stock of CollPlant Biotechnologies is held by institutions.

CLGN Stock Analysis - Frequently Asked Questions

How have CLGN shares performed this year?

CollPlant Biotechnologies' stock was trading at $6.39 at the beginning of 2024. Since then, CLGN shares have decreased by 33.8% and is now trading at $4.23.
View the best growth stocks for 2024 here.

How were CollPlant Biotechnologies' earnings last quarter?

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) issued its quarterly earnings results on Thursday, August, 24th. The company reported $0.49 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.83. The business earned $10.18 million during the quarter, compared to analyst estimates of $0.26 million. CollPlant Biotechnologies had a negative net margin of 2,535.70% and a negative trailing twelve-month return on equity of 65.98%.

When did CollPlant Biotechnologies IPO?

CollPlant Biotechnologies (CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager.

Who are CollPlant Biotechnologies' major shareholders?

CollPlant Biotechnologies' top institutional shareholders include Villere ST Denis J & Co. LLC (4.23%), Pinnacle Associates Ltd. (4.09%) and Benjamin Edwards Inc. (0.21%).

How do I buy shares of CollPlant Biotechnologies?

Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of CollPlant Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CollPlant Biotechnologies investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Ginkgo Bioworks (DNA), Globant (GLOB), Luminar Technologies (LAZR) and Saia (SAIA).

Company Calendar

• Last Earnings: 8/24/2023
• Today: 11/21/2024
• Next Earnings (Confirmed): 11/27/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical appliances & supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CLGN
• CUSIP: N/A
• CIK: 1631487
• Web: www.collplant.com
• Phone: 972732325600
• Fax: 972-73-232-5602
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.00
• High Stock Price Target: $11.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +160.0%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,020,000.00
• Net Margins: -2,535.70%
• Pretax Margin: -2,535.70%
• Return on Equity: -65.98%
• Return on Assets: -54.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.27
• Quick Ratio: 6.14

Sales & Book Value

• Annual Sales: $10.96 million
• Price / Sales: 4.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.47 per share
• Price / Book: 1.71

Miscellaneous

• Outstanding Shares: 11,450,000
• Free Float: 10,355,000
• Market Cap: $48.43 million
• Optionable: Optionable
• Beta: 0.44